(IN BRIEF) The EU‑funded AI4HF project is co‑designing, developing and evaluating a trustworthy AI tool to personalise heart failure care. Engaging over 200 stakeholders—including patients, clinicians and administrators—from Europe, South America and Africa, the project has held multiple workshops to … Read the full press release
Posted in Artificial Intelligence (AI), Business, Financial, France, Government, Healthcare, Industrial, Investment, Management, Marketing, News, Science, Technology
Tagged AI in healthcare, AI4HF, Amsterdam, Amsterdam UMC, Autumn 2025, Barcelona, bias mitigation, Brno, Clinical/Patient Working Groups, Dar es Salaam, ESC Digital Cardiology and AI Committee, European Heart Network, European Society of Cardiology, health literacy, heart failure, high‑dimensional data, Horizon Europe Framework, lifestyle recommendations, Lima, multi‑stakeholder workshops, partnership, personalised medicine, personalised risk assessment, Professor Folkert W. Asselbergs, shared decision-making, SHINE 2Europe, symptom interpretation, trustworthy AI
(IN BRIEF) The FDA has accepted AstraZeneca’s sBLA for Imfinzi as a perioperative immunotherapy regimen in resectable early‑stage and locally advanced gastric and GEJ cancers, granting Priority Review with a decision expected in Q4 2025. The application leverages MATTERHORN Phase III data … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged 2025 decision, adjuvant, AstraZeneca, breakthrough therapy designation, clinical paradigm shift, durvalumab, early-stage, EFS hazard ratio, event-free survival, FDA priority review, FLOT chemotherapy, gastric cancer, gastroesophageal junction cancer, high unmet need, Imfinzi, Levi Garraway, locally advanced, MATTERHORN Phase III, neoadjuvant, overall survival, Perioperative Immunotherapy, resectable, sBLA, Susan Galbraith
(IN BRIEF) Roche’s ongoing Phase Ib/IIa Brainshuttle™ AD study of trontinemab shows that 91 percent of participants reach amyloid PET negativity, with ARIA‑E rates under 5 percent. The company has outlined Phase III TRONTIER 1 and 2 trials in early symptomatic Alzheimer’s for 2025, plus a planned … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged Alzheimer’s Association International Conference, amyloid plaques, amyloid‑beta monoclonal antibody, ARIA‑E, blood‑based biomarker, blood‑brain barrier, Brainshuttle, centiloids, clinical dementia rating sum of boxes, cognitive decline, diagnostics, early diagnosis, Elecsys pTau217, Levi Garraway, Matt Sause, PET negativity, Phase Ib/IIa, Phase III TRONTIER 1, Phase III TRONTIER 2, preclinical Alzheimer’s, pTau181, pTau217/Ab42 ratio, Roche, sustainability of clinical trials, TRAVELLER, trontinemab
(IN BRIEF) GSK has entered into a multi-programme development and licensing agreement with Hengrui Pharma to advance up to 12 innovative therapies, including HRS-9821, a potentially best-in-class PDE3/4 inhibitor currently in clinical trials for COPD. The deal includes $500 million … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged AI-era medicine, biopharma partnership, Chronic obstructive pulmonary disease, clinical development, cloud healthcare, COPD treatment, drug innovation, drug pipeline, dry powder inhaler, Frank Jiang, global health, GSK, Hart-Scott-Rodino Act, Hengrui Pharma, HRS-9821, immunology, inflammation, licensing agreement, milestone payments, novel therapeutics, oncology, partnership, PDE3/4 inhibitor, pharmaceutical collaboration, phase I trials, respiratory medicine, Tony Wood
(IN BRIEF) Pfizer and BioNTech have received a positive recommendation from the EMA’s CHMP for their LP.8.1-adapted monovalent COVID-19 vaccine, COMIRNATY® LP.8.1, for individuals aged six months and older. This updated vaccine offers improved immune protection against prevalent SARS-CoV-2 subvariants, … Read the full press release
Posted in Business, Germany, Healthcare, Industrial, News, Pharma & Biotech, Science, Technology
Tagged BioNTech, booster, CHMP, COMIRNATY LP.8.1, COVID-19 vaccine, EMA, EU vaccine rollout, European Commission, immune response, LP.8.1 variant, mRNA technology, mRNA Vaccine, NB.1.8.1 variant, Pandemic Preparedness, pediatric COVID vaccine, Pfizer, public health, SARS-CoV-2, vaccine adaptation, XFG variant
(IN BRIEF) AstraZeneca’s Trixeo Aerosphere has received a positive opinion from the EMA’s CHMP for use with a new propellant that offers a 99.9% reduction in Global Warming Potential compared to traditional formulations. Trixeo becomes the first pressurised metered-dose inhaler … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged Ambition Zero Carbon, AMPLIFY Phase III trial, AstraZeneca, Barbara Eichhorst, Breztri, BTK inhibitor, budesonide, Calquence, chemoimmunotherapy, CHMP, chronic lymphocytic leukaemia, climate action in pharma, clinical trial, CLL, COPD, Dave Fredrickson, EMA, environmental sustainability, European approval, European Commission approval, European Union, fixed-duration regimen, formoterol fumarate, Frederik Trinkmann, glycopyrronium, hematologic diseases, hematology, Honeywell, inhalers, leukemia, low GWP, next-generation propellant, obinutuzumab, oncology, pMDI, progression-free survival, Respiratory Care, Ruud Dobber, Susanna Palkonen, Sustainable Healthcare, treatment option, Trixeo Aerosphere, venetoclax
(IN BRIEF) Novo Nordisk has received a positive opinion from the European Medicines Agency’s CHMP recommending label expansion for Alhemo® (concizumab) to include adolescents and adults with haemophilia A and B without inhibitors. Backed by robust data from the explorer8 … Read the full press release
Posted in Business, Denmark, Healthcare, News, Pharma & Biotech, Science, Technology
Tagged Alhemo®, bleeding disorder, CHMP, concizumab, EMA, European Commission, explorer8 trial, Haem-A-QoL, Haemophilia A, haemophilia B, haemophilia treatment, Martin Holst Lange, monoclonal antibody, Novo Nordisk, patient-reported outcomes, pen-injector, SF-36v2, subcutaneous prophylaxis, thrombin production, tissue factor pathway inhibitor
(IN BRIEF) The European Commission has approved Fresenius Kabi’s denosumab biosimilars, Conexxence® and Bomyntra®, for all uses of the originator product. These include osteoporosis treatment for postmenopausal women and at-risk men, mitigation of treatment-related bone loss, prevention of skeletal complications … Read the full press release
Posted in Business, Environment, Financial, Germany, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged #FutureFresenius, Biopharma platform, Bomyntra, cancer metastasis to bone, Conexxence, denosumab biosimilar, Europe, European Commission approval, Fresenius, Fresenius Kabi, Fresenius Kabi Deutschland GmbH, giant cell tumor of bone, high-quality biosimilars, osteoporosis, postmenopausal women, registered trademarks, skeletal complications, treatment-related bone loss
(IN BRIEF) University of Exeter researchers found that two weeks of twice-daily, nitrate-rich beetroot juice lowered blood pressure in older adults but not in younger ones, likely because of age-specific changes in mouth bacteria. The randomized crossover study—39 participants under … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Science, Technology, United Kingdom
Tagged ageing, BBSRC Industrial Partnership Award, beetroot juice, blood pressure, cardiovascular health, celery, dietary nitrate supplementation, Dr Lee Beniston, Exeter Clinical Trials Unit, fennel, Free Radical Biology and Medicine, kale, Neisseria, NIHR Exeter Clinical Research Facility, nitrate-rich diet, nitric oxide, Older Adults, oral microbiome, Prevotella, Professor Andy Jones, Professor Anni Vanhatalo, rocket, spinach, University of Exeter
(IN BRIEF) A Luxembourg–South Korea–USA consortium has launched the International Health Data Space Initiative (IHDSI) to create a federated, secure and privacy‑compliant platform for cross‑border health data integration, collaborative clinical research and translational innovation. Led by the Luxembourg Institute of … Read the full press release
Posted in Artificial Intelligence (AI), Business, Education, Financial, Government, Healthcare, Industrial, Investment, Luxembourg, Management, Marketing, News, Science, Technology
Tagged AI driven analytics, autonomous platforms, Big Data Analytics, bladder cancer cohort, Cancer, Cipherome, Clinical Working Group, cloud based analytics, CMP IaaS PaaS DevOps AIaaS AIOps, Compass platform, data silos, EHDS, epidemiology, European Health Data Space, feasibility study, federated data connector, Gaia-X, genomics, governance models, health data integration, hyperscale LLM, IHDSI, International Health Data Space Initiative, joint clinical research, Joint Steering Committee, LIH, Luxembourg Institute of Health, multi omics data, National Cancer Center Korea, NAVER Cloud Corporation, NCCK, Okestro, oncology biomarkers, Parkinson’s disease cohort, partnership, patient centric healthcare, precision medicine, precision oncology strategies, privacy-preserving, scalable computing, secure interoperable access, secure virtual environments, strategic alliance, systems biomedicine, Technical Working Group, translational innovation, translational research
(IN BRIEF) The Scientific Robotics Academy at SAMS in Oban has launched a three-day course, Environmental Monitoring using Multi-Platform Technology (3–5 September), to train those responsible for environmental oversight—spanning land, coast and sea—in deploying robotic platforms and sensors. Backed by … Read the full press release
Posted in Artificial Intelligence (AI), Business, Education, Environment, Financial, Government, Industrial, Investment, Management, Marketing, News, Science, Technology, United Kingdom
Tagged Argyll and Bute Council, autonomous platforms, BlueFloat Energy, bridging developers and end users, Dr Phil Anderson, environmental management, environmental monitoring, IMarEST, Limosaero, marine science, Math Campbell-Sturgess, Nadara Partnership, NGOs, Oban Airport, robotics systems, SAMS Oban, Scientific Robotics Academy, Scotland innovation hub, Scottish Association for Marine Science, solar powered drone, sustainability, terrestrial coastal marine, UK Shared Prosperity Fund, UKSPF
(IN BRIEF) Sanofi has agreed to acquire UK-based Vicebio for $1.15 billion upfront plus up to $450 million in milestones, with closing anticipated in Q4 2025. The deal adds an early-stage bivalent RSV/hMPV vaccine (VXB‑241, in Phase 1 for older adults) and … Read the full press release
Posted in Artificial Intelligence (AI), Business, Financial, France, Government, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged acquisition, AI-powered biopharma, Daniel Watterson, Emmanuel Hanon, fully liquid combination vaccines, Jean-François Toussaint, Keith Chappell, lower respiratory tract infections, Medicxi, Molecular Clamp technology, non-mRNA vaccine, Older Adults, partnership, Paul Young, pneumonia, prefilled syringes, regulatory approvals, respiratory vaccines pipeline, seasonal surges, Tags: Sanofi, UniQuest, University of Queensland, Vicebio
(IN BRIEF) TUM researchers estimate that lightning kills about 320 million trees each year—damage that has been difficult to detect and previously underestimated. By augmenting the LPJ-GUESS global vegetation model with observational data and global lightning patterns, the team quantified … Read the full press release
Posted in Business, Education, Environment, Financial, Germany, Industrial, Investment, Management, Marketing, News, Science, Technology
Tagged Andreas Krause, biomass decay, biomass loss, Boreal Forests, carbon storage, climate models, disturbance ecology, forest structure, Global Change Biology 2025, global vegetation model, increasing lightning frequency, Konstantin Gregor, land surface–atmosphere interactions, lightning-induced tree mortality, LPJ-GUESS, sustainability, Technical University of Munich, temperate forests, tropical forests, TUM, TUM School of Life Sciences, wildfire emissions, wildfires living plants
(IN BRIEF) University of Glasgow physicist Dr David Mahon and artist/instrument maker Lomond Campbell have created the Muonophone, a hand-built device that converts detections of cosmic-ray muons into live music and visuals. Rooted in Mahon’s muography research—using muons to map … Read the full press release
Posted in Business, Education, Financial, Industrial, Investment, Management, Marketing, News, Science, Technology, United Kingdom
Tagged audiovisual art, cosmic ray music, cosmic rays, Dr. David Mahon, Edinburgh Festival Fringe, French Institute Edinburgh, installation, Institute of Physics in Scotland, live performances, Lomond Campbell, Lynkeos Technology, Made in Scotland Showcase, MŮO, muography, Muonophone, muons, music technology, particle detectors, science outreach, Sonica Glasgow, University of Glasgow
(IN BRIEF) HOCHTIEF has been commissioned by the University of Duisburg-Essen to construct a new interdisciplinary research center on its Essen campus and to convert a historic boiler house in Krefeld into a state-of-the-art event venue. The five-story research facility … Read the full press release
Posted in Business, Construction, Education, Financial, Germany, Industrial, Infrastructure & Utilities, Investment, Management, Marketing, News, Science, Technology
Tagged campus development, cultural infrastructure, e-mobility, energy research, environmental science, Essen campus, event center, higher education, HOCHTIEF, interdisciplinary science, Krefeld, laboratory construction, Mies van der Rohe campus, nanotechnology, partnership, photovoltaics, research center, sustainability, University of Duisburg-Essen, urban redevelopment
(IN BRIEF) Final overall survival results from AstraZeneca’s FLAURA2 Phase III trial confirm that combining Tagrisso with chemotherapy significantly improves survival for patients with first-line advanced EGFR-mutated NSCLC. The data reinforce Tagrisso as the foundational therapy in this setting, building … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged ADAURA trial, ADAURA2, adjuvant therapy, AstraZeneca, cancer survival, chemotherapy, EGFRm NSCLC, EMA, FDA, FLAURA2 trial, global clinical trial, LAURA trial, lung cancer treatment, NeoADAURA, non-small cell lung cancer, oncology, osimertinib, overall survival, Pasi A. Jänne, pemetrexed, platinum-based treatment, progression-free survival, Susan Galbraith, Tagrisso, targeted therapy
(IN BRIEF) Two recent PhD graduates from the University of Groningen, M. Kokkorakis and K. Zhong, have secured prestigious Rubicon grants from the Netherlands Organisation for Scientific Research (NWO). Over the next two years, Kokkorakis will work at Yale School … Read the full press release
Posted in Awards, Business, Education, Financial, Industrial, Investment, Management, Marketing, Netherlands, News, Science, Technology
Tagged academic careers, AI in enzyme engineering, Awards, biocatalysts, Dutch research, Green Chemistry, Harvard Medical School, humanized liver models, international research, K. Zhong, leadership, lipids and immunity, liver disease research, M. Kokkorakis, metabolic diseases, NWO, protein dynamics, Rubicon programme, spectroscopy, sustainable science, University of Groningen, Yale School of Medicine
(IN BRIEF) Sanofi has completed its purchase of Blueprint Medicines, acquiring the approved systemic mastocytosis therapy Ayvakit/Ayvakyt (avapritinib), along with two pipeline candidates: elenestinib (a KIT D816V inhibitor in Phase 2/3 HARBOR, NCT04910685) and BLU‑808 (a wild‑type KIT inhibitor). The $129.00‑per‑share … Read the full press release
Posted in Business, Financial, France, Government, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged $129.00 per share, avapritinib, Ayvakit, Ayvakyt, Blueprint Medicines, BLU‑808, contingent rights, elenestinib, GIST, HARBOR, KIT inhibitor, MERGER, NASDAQ delisting, NCT04910685, partnership, PDGFRA D842V, Sanofi, SM, sustainability, systemic mastocytosis, tender offer
All metal flexible wheels for Lunar rovers (IN BRIEF) HTR, based in Central Greece, is now offering its patented, all‑metal flexible wheels—designed since 2016 to endure the Moon’s extreme temperatures (–180 °C to +130 °C) and radiation—for commercial purchase worldwide via www.htr.gr … Read the full press release
Posted in Automotive, Aviation & Aerospace, Defence, France, Greece, Science, Technology, Transportation & Logistics
Tagged all metal flexible wheels, Dr. Anastasios Katelouzos, elastic metal wheels, Engineering Models of all-metal flexible flight wheels, HTR, lunar rovers, Lunar wheel, Metal flexible wheel, NASA, Non pneumatic all metal wheel, planetary exploration vehicles, Research Community, Roboshop, rovers, terrestrial vehicles, vehicle for the moon, wheels for lunar use
(IN BRIEF) PATRIZIA has finalised an 81,000 sq ft pre‑let to Cleveland Clinic London at 40 Grosvenor Place for a new cancer centre opening in 2027. The centre will span seven floors and feature advanced treatment capabilities—systemic therapies, radiotherapy and outpatient care. PATRIZIA’s … Read the full press release
Posted in Business, Environment, Financial, Government, Industrial, Infrastructure & Utilities, Investment, Management, Marketing, News, Real Estate, Science, Technology, United Kingdom
Tagged 40 Grosvenor Place, asset repositioning, cancer treatment centre, CBRE, central London real estate, Christie Wright, Cleveland Clinic London, clinical space, Knight Frank, outpatient care, partnership, PATRIZIA, pre‑let, radiotherapy, systemic therapies
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?